Statistics

Total Visits

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati78

Select a period of time:

Number of views in the range

Views
GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutati24

Views

Views
October 20250
November 20256
December 20253
January 20261
February 20260
March 20266
April 20268
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States7
Brazil4
Ecuador2
Mexico2
South Africa2
Argentina2
Germany1
France1
United Kingdom1
Netherlands1
 

Top cities views

Views
San Jose3
Guayaquil2
Mexico City2
Cape Town2
Amsterdam1
Frankfurt am Main1
Morón1
Nogoyá1
Panama City1
Rio de Janeiro1